Development of a novel oral vaccine platform using spores of probiotic, Clostridium butyricum, for heterologous antigen display

使用益生菌丁酸梭菌孢子开发新型口服疫苗平台，用于异源抗原展示

• 批准号: 2103761
• 金额: --
• 依托单位: University of Nottingham
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2103761
• 关键词: Development; novel; oral; vaccine; platform

The original project was focused on exploiting Escherichia coli as a chassis strain for the expression and purification of protective antigens from Clostridium difficile for coating onto a liposomal-based mucosal vaccine platform. This project focuses on genetically engineering the probiotic, Clostridium butyricum, to express C. difficile antigens on the spore coat. The recombinant C. butyricum spore will act as a live vaccine targeting the intestinal mucosa following oral administration.

最初的项目集中于利用大肠杆菌作为底盘菌株，用于表达和纯化来自艰难梭菌的保护性抗原，用于涂覆到基于脂质体的粘膜疫苗平台上。本项目的重点是通过基因工程改造酪酸梭菌，使其表达C。孢子衣上的艰难梭菌抗原重组C.丁酸菌孢子在口服给药后将作为靶向肠粘膜的活疫苗。